Aakaar Medical Technologies Limited — PPTs, 15-05-2026: Investor Presentation

Aakaar Medical Technologies reported a strong H2 FY26, rebounding from H1 challenges due to tightened credit. For FY26, revenue grew 8.6% YoY to 67 Cr, while Profit After Tax (PAT) increased 10% YoY to 6.63 Cr. EBITDA rose 12% YoY to 11 Cr, with a 16.39% margin. Aesthetics products (89%) and device consumables (4%) continue to drive recurring business, with significant growth in injectables and professional skincare.

The company's strategy focuses on cash-first billing, expanding into Tier 2-3 cities, and increasing its own-brand portfolio to 37% for better margins. Key growth levers include outsourcing capital-intensive activities and enhancing its robust distribution network by moving to over 90% sales through stockists for improved logistics and receivables. Aakaar also trains doctors extensively through programs like MICA, fostering market growth. Debtor days improved from 209 to 167.

Recent developments include the launch of four new high-growth brands: LETYBO®, SAYPHA® Dermal Filler, VM Corp. Regenerative Suite, and XOMAGE Plant Exosomes. A significant update is the launch of XELIX, an India-first Doctor-Owned, Doctor-Operated (DODO) medical aesthetics platform, aiming for 50 clinics in FY26 and expanding to 100+ clinics in FY27. Management is focused on sustained profitability through leaner operations and a broader customer base.